Journal
CANCER CELL
Volume 35, Issue 6, Pages 830-849Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2019.04.002
Keywords
-
Categories
Funding
- Excellence of Science [EOS 30826052 MODEL-IDI]
- Research Foundation Flanders [FWO G0B7118N]
- VLIR-UOS [TEAM2018-SEL018]
- Charcot Foundation
- Stichting Tegen Kanker [FAFC/2018/1250]
- Ghent University
- VIB
- European research program TOP-BOF [32254]
- European research program FWO [G0C0119N]
- Belgian grants [EOS 30826052 MODEL-IDI]
- Flemish grants (Research Foundation Flanders) [FWO G.0C31.14N, G.0C31.14N, G.0C37.14N, FWO G0E04.16N, G.0C76.18N, G.0B71.18N]
- Ghent University [BOF16/MET_V/007]
- Foundation against Cancer [FAF-F/2016/865]
Ask authors/readers for more resources
One of the key challenges in cancer research how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the r. An reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available